Skip to main content

Carlsmed, Inc.

corporate_fare Company Profile

Carlsmed, Inc.

CARL·NASDAQ·Industrial Applications And Services·CIK 0001794546

aprevo is a commercial-stage medical technology company that develops AI-enabled personalized spine surgery solutions. The company aims to make its aprevo Technology Platform the standard of care for spine fusion surgery, with a mission to improve outcomes and decrease healthcare costs for spine surgery. The aprevo Technology Platform was designed to address limitations in traditional lumbar and cervical spine fusion surgery, aiming to optimize patient outcomes and reduce the need for revision surgeries. The technology uses AI-enabled, outcome-based algorithms to create personalized surgical plans for spine fusion. The aprevo surgical kit provided to customers contains interbody implants designed for a custom vertebral fit for each patient's specific pathology and bone topography, along with single-use surgical instruments. The aprevo Technology Platform assists surgeons in achieving proper spinal alignment for patients with degenerative disc disease ("DDD"), which can improve clinical outcomes and reduce the likelihood of revision surgeries. aprevo currently markets the aprevo Technology Platform for lumbar and cervical spine fusion surgeries. DDD involves the progressive breakdown of spinal discs, which provide mobility and shock absorption between vertebrae. This disease occurs naturally with age and can be accelerated by factors such as injury, repetitive loading, obesity, or genetic predisposition. Adult spinal deformity ("ASD") is a more severe form of DDD, characterized by systematic structural abnormalities and/or abnormal curvature of the spine, often affecting multiple levels. These conditions frequently lead to loss of disc height and spine function, chronic pain, disability, and other chronic spinal pathologies. Surgical intervention may become necessary when these conditions progress and patients experience debilitating pain or disabilities. One study estimated the overall prevalence of diagnosed DDD was 27.3% for individuals over the age of 65, increasing with age. Non-surgical interventions are typically the initial treatment for DDD, focusing on managing symptoms and slowing disease progression without invasive procedures. Surgical interventions may be required when non-surgical treatments fail to alleviate debilitating symptoms or disabilities.

Carlsmed, Inc. (NASDAQ:CARL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for CARL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for CARL spans 10-Q, 8-K, 144, 10-K.

Recent high-impact activity:

  • Carlsmed 10-Q Details Q3 Revenue of $21.6M, 77.3% Gross Margin and $80.3M Liquidity
  • Carlsmed Q3 Revenue Jumps 65% to $21.6M, Full-Year Guidance Raised to $78-80M
  • Q3 Revenue Jumps 65% to $21.6M, Full-Year Guidance Raised to $78-80M
  • Carlsmed Names Richard Heppenstall CFO, Reaffirms FY26 Revenue Guidance of $74–78M
  • Carlsmed Sues DeGen Medical Over Eight Spine Surgery Patents

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$50.51M
Net Income
-$29.63M
Diluted EPS
-$2.12
Op. Cash Flow
-$28.98M
Free Cash Flow
-$29.62M
Gross Profit
$38.04M
Operating Income
-$30.57M
Cash & Equivalents
$85.79M
Total Debt
$15.35M
Debt / Equity
0.16×
Net Margin
-58.7%
Shares Outstanding
26.6M sh
Source: 10-K · filed 2026-02-25 · accession 0001193125-26-071551

Short Interest & Short Volume

15.07 days to cover

FINRA reported short interest of 1,241,498 shares in CARL as of the October 30, 2026 settlement, a 13.4% increase from the prior period — about 15.1 days to cover at its recent average daily volume. On November 19, 2026, 46.5% of CARL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,241,498 shares as of October 30, 2026
Change vs prior period▲ 13.4%
Days to cover15.07 at avg daily volume of 82,380
Daily short volume (FINRA facilities)46.5% of 28,094 shares on November 19, 2026
5-day average short volume29.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CARL, detected from its recent SEC filings.

1 shelf registration

$250M Universal Shelf Registered · No Immediate Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

$17.39 +0.99% today
52-week range · as of 2026-11-10 $8.5 – $17.39
Market cap
$476.28M
Volume
241.4K (1.8× avg)
3-mo avg 136.6K
Live data · 2026-11-20 20:56 UTC · Market open

show_chartPrice Chart

Loading chart...

feed CARL - Latest Insights

CARL
Nov 10, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.71
Real-time Price: $17.39 info
Change: +$2.68 (+18%) info
Market Cap: $476.283M info
CARL
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.71
Real-time Price: $17.39 info
Change: +$2.68 (+18%) info
Market Cap: $476.283M info
CARL
Nov 10, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $14.71
Real-time Price: $17.39 info
Change: +$2.68 (+18%) info
Market Cap: $476.283M info
CARL
Sep 30, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.09
Real-time Price: $17.39 info
Change: +$3.30 (+23%) info
Market Cap: $476.283M info
CARL
Sep 15, 2026, 7:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.23
Real-time Price: $17.39 info
Change: +$2.16 (+14%) info
Market Cap: $476.283M info
CARL
Aug 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.59
Real-time Price: $17.39 info
Change: +$4.80 (+38%) info
Market Cap: $476.283M info
CARL
May 05, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.28
Real-time Price: $17.39 info
Change: +$8.11 (+87%) info
Market Cap: $476.283M info
CARL
May 05, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.28
Real-time Price: $17.39 info
Change: +$8.11 (+87%) info
Market Cap: $476.283M info
CARL
May 05, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.28
Real-time Price: $17.39 info
Change: +$8.11 (+87%) info
Market Cap: $476.283M info
CARL
Mar 02, 2026, 4:54 PM EST
Filing Type: 144
Importance Score:
8
Price at Filing: $13.15
Real-time Price: $17.39 info
Change: +$4.24 (+32%) info
Market Cap: $476.283M info
CARL
Feb 25, 2026, 4:09 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $12.56
Real-time Price: $17.39 info
Change: +$4.83 (+38%) info
Market Cap: $476.283M info
CARL
Feb 25, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.56
Real-time Price: $17.39 info
Change: +$4.83 (+38%) info
Market Cap: $476.283M info
CARL
Jan 12, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.69
Real-time Price: $17.39 info
Change: +$4.70 (+37%) info
Market Cap: $476.283M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets